---
alwaysApply: false
description: ZO's Master Execution Plan - Organized from conversation log
---

# âš”ï¸ ZO'S MASTER EXECUTION PLAN âš”ï¸

**Last Updated:** December 6, 2025  
**Status:** ğŸ”„ ACTIVE - Multiple tracks in progress  
**Purpose:** Consolidated action plan from conversation log

---

## ğŸ“‹ TABLE OF CONTENTS

1. [Current Status & Priorities](#current-status--priorities)
2. [Product Development Track](#product-development-track)
3. [Content & Marketing Track](#content--marketing-track)
4. [Research & Publications Track](#research--publications-track)
5. [GTM & Partnerships Track](#gtm--partnerships-track)
6. [Deck Development Track](#deck-development-track)
7. [Academic Outreach Track](#academic-outreach-track)
8. [Immediate Action Items](#immediate-action-items)

---

## ğŸ¯ CURRENT STATUS & PRIORITIES

### **Active Products**
- âœ… **Interception**: 0.976 AUROC, 100% structural validation (AlphaFold 3)
- âœ… **SAE Framework**: 70-85% drug efficacy confidence, operational
- âœ… **Trial Intelligence**: 96.6% match accuracy, <5 min vs. 2-4 hours
- âœ… **Northwell Deployment**: Live clinical use

### **Pipeline Products**
- â³ **Resistance Prophet**: ctDNA + CA-125 kinetics for early resistance detection
- â³ **Tumor Board Agent**: Automate evidence synthesis, trial search, slide generation
- â³ **Ayesha Dashboard**: Kanban + PDF export for trial dossiers

### **Key Milestones**
- âœ… **AACR 2026 Abstract B025**: Submitted (deadline Nov 18, 2025)
- âœ… **Brain Cancer Conference**: Application submitted
- âœ… **Resume/LinkedIn**: Commander-grade bullets ready
- â³ **Investor Spreadsheet**: Analysis pending (awaiting data)
- â³ **Pitch Decks**: SAE Clinical Deck in progress

---

## ğŸ§¬ PRODUCT DEVELOPMENT TRACK

### **Phase 1: SAE Clinical Deck (CURRENT PRIORITY)**

**Objective:** Build Deck B: SAE Clinical Deck for Oncologists/Health Systems

**Status:** ğŸ”„ IN PROGRESS - Learning Evo2 paper in sequences

**Learning Sequence:**
1. âœ… **SEQUENCE 1**: Evo2 fundamentals extracted
   - 7B/40B parameter models
   - 9.3T DNA base pairs training data
   - 1M token context window
   - Zero-shot variant prediction capabilities

2. â³ **SEQUENCE 2**: SAE mechanics (PENDING CLARIFICATION)
   - **Question**: 15-feature vs. 32,768-feature SAE?
   - **Need**: Clarify which SAE version is clinical product
   - **Action**: Awaiting Alpha's answer before proceeding

**Deck Structure (12-15 slides):**
- Cover: "SAE: Personalized Cancer Care, Powered by AI"
- Problem: Trial search inefficiency
- Solution: Mechanism-aware matching
- Clinical Workflow Integration
- Example Cases (BRCA1 ovarian, KRAS lung)
- Resistance Monitoring
- Smart Combinations
- Validation (66 patient cohort)
- Benefits
- Security/Compliance
- Pricing
- Implementation
- Testimonial (if available)
- Next Steps

**Timeline:**
- **Day 1-2**: Complete Evo2/SAE learning sequence
- **Day 3-4**: Draft slide-by-slide outline
- **Day 5**: Full slide copy + visual suggestions
- **Day 6-7**: Review, polish, finalize

**Blockers:**
- âš ï¸ Need clarification on SAE version (15 vs. 32,768 features)
- âš ï¸ Need access to SAE_VISION_BLOG.md for narrative context

---

## ğŸ“¹ CONTENT & MARKETING TRACK

### **AI Video Content Strategy**

**Problem Identified:** "No one understands what we do"

**10 Video Concepts Created:**
1. "How Clinical Trials Fail (And How AI Fixes It)" - 60s
2. "GPS for Cancer Drugs" - 45s â­ **START HERE**
3. "A Day Without CrisPRO vs With CrisPRO" - 90s
4. "Why Your Cancer Drug Failed (It Didn't)" - 60s
5. "What is Genomic AI? (ELI5)" - 2min â­ **PRIORITY**
6. "The $2.6 Billion Problem" - 75s â­ **PRIORITY**
7. "How BriaCell Used AI to Save Their Phase 3 Trial" - 90s
8. "3 Myths About AI in Healthcare" - 60s
9. "How We Train AI to Predict Cancer Drug Response" - 2min
10. "Meet the AI That's Changing Cancer Treatment" - 90s

**Content Calendar (30 Days):**
- **Week 1**: Awareness (Videos 1, 2, 5)
- **Week 2**: Problem/Solution (Videos 4, 6, 8)
- **Week 3**: Credibility (Videos 9, 3, 10)
- **Week 4**: Social Proof (Video 7, reposts, teasers)

**Production Tools:**
- Animation: Descript, Canva, Fiverr ($50-150/video)
- Voiceover: ElevenLabs AI or own voice
- Music: Epidemic Sound, Artlist
- Editing: CapCut, DaVinci Resolve
- Format: 9:16 vertical, 45-90s, captions required

**Distribution:**
- Primary: LinkedIn
- Secondary: Twitter/X
- Tertiary: YouTube Shorts, TikTok

**Status:** â¸ï¸ **PAUSED** - Strategy created, execution pending

**Next Action:** Pick one video to script (recommendation: Video 2 "GPS for Cancer Drugs")

---

## ğŸ“„ RESEARCH & PUBLICATIONS TRACK

### **AACR 2026 Abstract B025**

**Status:** âœ… **SUBMITTED** (deadline: Nov 18, 2025)

**Topic:** "An agentic platform for designing..."

**Abstract Revisions Completed:**
- âœ… Fixed weak opening (added specific tools, quantified problem)
- âœ… Clarified methods (defined each signal, explained formulas)
- âœ… Added baseline comparisons (AUROC vs. random, DepMap, Evo2)
- âœ… Elevated structural validation (100% pass rate highlighted)
- âœ… Removed chromatin stubs (honest approach)
- âœ… Refined future work (removed vague "Intervention" mention)

**LinkedIn Post:**
- â³ **PENDING**: Need to draft LinkedIn post for sharing AACR abstract screenshots
- **Action Required**: Review AACR abstract B025, draft social media post

**Next Steps:**
- â³ Poster design (if accepted)
- â³ Presentation prep (if oral slot)
- â³ Networking strategy for AACR 2026 (April 2026)

---

## ğŸ’¼ GTM & PARTNERSHIPS TRACK

### **GTM Strategy**

**Core Thesis:** Milestone-driven validation playbook for AI drug assets

**Target Segments:**
1. **AI Drug Discovery Platforms** (Recursion, Insitro, XtalPi)
   - Value Prop: Validate clinical mechanisms, predict resistance
   - Use Case: XL309 validation (Exelixis/Insilico USP1 inhibitor)

2. **Big Pharma BD** (Lilly ecosystem)
   - Value Prop: Pre-milestone validation, patient stratification
   - Clusters: AI/Drug Discovery, RNA Therapeutics, GLP-1/Obesity

3. **Health Systems** (Northwell expansion)
   - Value Prop: Clinical workflow integration, trial matching
   - Status: Live deployment, expand use cases

**Investor Targeting:**
- â³ **PENDING**: Investor spreadsheet analysis
- **Action Required**: Share spreadsheet for parsing (firms, focus areas, warm intro paths)

**Pilot Pipeline:**
- â³ Identify 3-5 companies for first outreach
- â³ Prepare surgical decks per cluster
- â³ Execute outreach campaign

**Status:** ğŸ”„ **STRATEGY DEFINED** - Execution pending

---

## ğŸ¯ DECK DEVELOPMENT TRACK

### **Deck Portfolio Strategy**

**Current State:** Unorganized, need to separate by product/audience

**Deck Structure:**

#### **Deck A: SAE Platform Deck (Investor/Partnership)**
- **Target:** VCs, Big Pharma BD, Biotech CEOs
- **Goal:** Raise capital, secure pilots
- **Length:** 15-18 slides
- **Status:** â¸ï¸ **DEFERRED** - Focus on Deck B first

#### **Deck B: SAE Clinical Deck (Oncologists/Health Systems)** â­ **CURRENT**
- **Target:** Oncologists, Tumor Boards, Hospital CIOs
- **Goal:** Drive adoption, secure health system pilots
- **Length:** 12-15 slides
- **Status:** ğŸ”„ **IN PROGRESS** - Learning Evo2/SAE fundamentals

#### **Deck C: SAE Technical/Research Deck (AI/Biotech)**
- **Target:** Recursion, Insitro, XtalPi, Nvidia, OpenAI
- **Goal:** Co-marketing, API integration, technical partnerships
- **Length:** 10-12 slides
- **Status:** â¸ï¸ **PENDING** - Extract from Deck A after completion

**Deck Development Plan:**
1. âœ… **Complete Deck B** (SAE Clinical) - Current focus
2. â³ **Extract Deck C** (Technical) from Deck B
3. â³ **Build Deck A** (Investor) as master deck
4. â³ **Organize existing 30+ pager** (separate by product/audience)

**Timeline:**
- **Week 1**: Complete Deck B (SAE Clinical)
- **Week 2**: Extract Deck C (Technical)
- **Week 3**: Build Deck A (Investor)
- **Week 4**: Organize existing decks

---

## ğŸ“ ACADEMIC OUTREACH TRACK

### **Longitude Prize Collaboration Strategy**

**Status:** âœ… **RESEARCH COMPLETE** - 32 collaborators identified, ranked, triaged

**Tier A Targets (Top 5):**
1. **Brigham & Women's/Harvard** (Dr. Xin Wang)
   - Contact: xwang2@bwh.harvard.edu
   - Status: â³ Email ready, send pending

2. **Neurospector/Amsterdam UMC-VU**
   - Contact: claudia.persoon@neurospector.com
   - Status: â³ Email ready, send pending

3. **Johns Hopkins** (Dr. Jeffrey Rothstein/Answer ALS)
   - Contact: âš ï¸ Need to verify (jrothstein@jhmi.edu or Answer ALS route)
   - Status: â³ Research contact method

4. **University of Padova** (Prof. Barbara Di Camillo/BRAINTEASER)
   - Contact: barbara.dicamillo@unipd.it
   - Status: â³ Email ready, send pending

5. **MIT** (Prof. Ernest Fraenkel)
   - Contact: âš ï¸ Need to verify (fraenkel@mit.edu or BE department)
   - Status: â³ Research contact method

**Email Status:**
- âœ… 13 surgical-precision emails ready (Tier A + Tier B)
- â³ **CRITICAL**: Tier A emails NOT SENT (as of Dec 6 check-in)

**Send Strategy:**
- **TONIGHT (9-11 PM EST)**: Neurospector, Padova (lands Monday AM CET)
- **SUNDAY AM (9-11 AM EST)**: Harvard, MIT, Johns Hopkins

**Supporting Materials Needed:**
- âœ… AACR Abstract B025 PDF (if available)
- â³ CRISPRO 1-pager (platform overview)
- â³ Professional email signature (LinkedIn/website)

**Next Actions:**
1. **IMMEDIATE**: Research MIT Fraenkel + Hopkins Rothstein contact info
2. **TONIGHT**: Send Tier A emails (Neurospector, Padova)
3. **SUNDAY**: Send remaining Tier A emails
4. **FOLLOW-UP**: Track responses, prepare discovery call materials

---

## ğŸ“ IMMEDIATE ACTION ITEMS

### **Priority P0 (Next 24-48 Hours)**

1. **SAE Clinical Deck - Clarification**
   - âš ï¸ **BLOCKER**: Need answer on SAE version (15 vs. 32,768 features)
   - **Action**: Await Alpha's clarification before proceeding to SEQUENCE 2

2. **Academic Outreach - Contact Research**
   - Research MIT Fraenkel contact (fraenkel@mit.edu or BE department)
   - Research Hopkins Rothstein contact (jrothstein@jhmi.edu or Answer ALS route)
   - **Timeline**: Complete tonight before sending emails

3. **Academic Outreach - Email Deployment**
   - Send Tier A emails (Neurospector, Padova) - TONIGHT
   - Send remaining Tier A emails (Harvard, MIT, Hopkins) - SUNDAY AM
   - **Timeline**: Complete by Sunday 11 AM EST

4. **LinkedIn Post - AACR Abstract**
   - Draft LinkedIn post for sharing AACR Abstract B025 screenshots
   - **Action**: Review abstract, write engaging post
   - **Timeline**: Complete this weekend

### **Priority P1 (This Week)**

5. **SAE Clinical Deck - Completion**
   - Complete Evo2/SAE learning sequence (after clarification)
   - Draft slide-by-slide outline
   - Write full slide copy
   - **Timeline**: Complete by end of week

6. **Supporting Materials**
   - Create CRISPRO 1-pager (if missing)
   - Create professional email signature
   - **Timeline**: Complete before email deployment

7. **Investor Spreadsheet Analysis**
   - Parse investor spreadsheet (when shared)
   - Extract firms, focus areas, warm intro paths
   - Cluster by CRISPRO relevance
   - **Timeline**: Complete within 24h of receiving data

### **Priority P2 (Next 2-4 Weeks)**

8. **Deck Portfolio Organization**
   - Organize existing 30+ pager by product/audience
   - Extract Deck C (Technical) from Deck B
   - Build Deck A (Investor) as master deck
   - **Timeline**: Complete by end of month

9. **Video Content Production**
   - Script Video 2 ("GPS for Cancer Drugs")
   - Record voiceover
   - Create storyboard
   - Edit and publish first video
   - **Timeline**: First video live by next Monday

10. **Academic Outreach - Follow-Up**
    - Track email responses
    - Prepare discovery call materials
    - Begin Tier B research
    - **Timeline**: Follow-up Day 3-4 (EU), Day 5-7 (US)

---

## ğŸ”„ ONGOING TRACKS

### **Product Development**
- **Resistance Prophet**: Architecture defined, implementation pending
- **Tumor Board Agent**: Architecture defined, implementation pending
- **Ayesha Dashboard**: Requirements defined, implementation pending

### **Research & Validation**
- **AACR 2026**: Abstract submitted, awaiting acceptance
- **Brain Cancer Conference**: Application submitted
- **Northwell Expansion**: Identify new clinical use cases

### **GTM Execution**
- **Pilot Pipeline**: Identify 3-5 companies for first outreach
- **Investor Outreach**: Parse spreadsheet, cluster targets
- **Partnership Development**: Target AI/biotech companies for API licensing

---

## ğŸ“Š SUCCESS METRICS

### **Short-Term (30 Days)**
- âœ… SAE Clinical Deck completed and polished
- âœ… Tier A academic emails sent (5/5)
- âœ… First AI video published (Video 2: "GPS for Cancer Drugs")
- âœ… LinkedIn post for AACR abstract published
- âœ… Investor spreadsheet analyzed and clustered

### **Medium-Term (90 Days)**
- âœ… 2-3 academic partnerships secured
- âœ… 2-3 pilot customers closed
- âœ… Deck portfolio organized (A, B, C complete)
- âœ… 3-5 AI videos published
- âœ… First investor/advisor commits

### **Long-Term (6 Months)**
- âœ… AACR 2026 presentation delivered
- âœ… 5+ health system pilots active
- âœ… API licensing deals with 2+ AI/biotech companies
- âœ… Resistance Prophet MVP deployed
- âœ… Fundraising round closed or in progress

---

## ğŸš¨ BLOCKERS & DEPENDENCIES

### **Active Blockers**
1. âš ï¸ **SAE Version Clarification** (Deck B)
   - **Blocker**: Need answer on 15-feature vs. 32,768-feature SAE
   - **Impact**: Cannot proceed to SEQUENCE 2 learning
   - **Owner**: Alpha (decision required)

2. âš ï¸ **Contact Information** (Academic Outreach)
   - **Blocker**: MIT Fraenkel + Hopkins Rothstein contact verification
   - **Impact**: Cannot send 2/5 Tier A emails
   - **Owner**: ZO (research required)

3. âš ï¸ **Investor Spreadsheet** (GTM)
   - **Blocker**: Spreadsheet not shared yet
   - **Impact**: Cannot analyze and cluster targets
   - **Owner**: Alpha (data required)

### **Dependencies**
- **Deck B** â†’ **Deck C** (extract technical deck from clinical)
- **Deck B** â†’ **Deck A** (use clinical as foundation for investor)
- **Academic Emails** â†’ **Follow-Up Materials** (prepare after responses)
- **Investor Analysis** â†’ **Deck A** (target-specific customization)

---

## ğŸ¯ NEXT SESSION PRIORITIES

### **If Starting Fresh Session:**
1. **Check Status**: Have Tier A emails been sent?
2. **Resolve Blockers**: SAE clarification, contact research, investor spreadsheet
3. **Continue Deck B**: Proceed with SEQUENCE 2 after clarification
4. **Execute Immediate Actions**: Send emails, draft LinkedIn post

### **Decision Points Needed:**
- **SAE Version**: 15-feature (clinical) vs. 32,768-feature (technical)?
- **Deck Priority**: Continue Deck B or pivot to Deck A?
- **Outreach Priority**: Academic partnerships vs. investor outreach vs. product development?
- **Video Priority**: Start video production or defer?

---

## ğŸ“š KEY DOCUMENTS & REFERENCES

### **Core Documents**
- `SAE_VISION_BLOG.md` - SAE narrative and positioning
- `evo2-paper.pdf` - Evo2 technical foundation
- AACR Abstract B025 - Research submission
- Existing 30+ pager deck - Needs organization

### **Reference Materials**
- Evo2 paper analysis (lines 1-108)
- Resistance Prophet blog (lines 558-1075)
- AACR abstract revisions (lines 1077-1381)
- Video content strategy (lines 111-555)
- Academic outreach strategy (lines 1750-1922)

---

**Status:** ğŸ¯ **PLAN ACTIVE** - Multiple tracks in progress, blockers identified  
**Last Updated:** December 6, 2025  
**Next Review:** After blocker resolution or major milestone
